BioCentury
ARTICLE | Financial News

ProQR files for IPO

August 16, 2014 1:13 AM UTC

ProQR Therapeutics B.V. (Leiden, the Netherlands) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Leerink Partners; Deutsche Bank; JMP Securities; and H.C. Wainwright. ProQR's QR-10, an RNA-based antisense oligonucleotide, is in preclinical development for cystic fibrosis. The company is developing the compound to be delivered via inhalation.

Next quarter, ProQR plans to submit an IND to FDA and a clinical trial application with EMA for a dose-escalation Phase Ib trial in CF patients with two copies of the delta F508 CF transmembrane conductance regulator (CFTR) mutation. Data from the trial are expected in 4Q15. ...